18 completed, 16 recruiting, 13 not yet recruiting, 9 active not recruiting. 20 Phase 2, 13 Not applicable, 12 Phase 3, 2 Phase 1, 1 Phase 4.
Follow Early Breast Cancer: new trials by email Literature Review of Early Breast Cancer trials Research Report on Early Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer Atirmociclib, giredestrant, Atirmociclib placebo - Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | Phase 3 | Not yet recruiting | Pfizer | 3800 | 2026-12-01 | 2026-10-22 |
| A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment Giredestrant - Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer | Phase 3 | Not yet recruiting | Hoffmann-La Roche | 1500 | 2026-10-30 | 2026-10-15 |
| A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer ZOLADEX - Advanced Breast Cancer, Early Breast Cancer | Phase 1 | Recruiting | TerSera Therapeutics LLC | 176 | 2026-10-30 | 2026-10-13 |
| A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) Giredestrant - Early Breast Cancer | Phase 3 | Recruiting | Genentech, Inc. | 300 | 2026-08-25 | 2026-10-20 |
| A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant Therapy Early Breast Cancer | Not yet recruiting | Hebei Medical University Fourth Hospital | 2000 | 2026-08-02 | 2026-04-20 | |
| Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial Tirzepatide, Letrozole (Aromatase Inhibitors) - Hormone-receptor-positive Breast Cancer, Early Breast Cancer | Phase 2 | Not yet recruiting | Universitaire Ziekenhuizen KU Leuven | 168 | 2026-08-01 | 2026-07-07 |
| Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone, In the control arm, the treatment will be as standard of care : chemo-endocrine therapy - Early Breast Cancer, Premenopausal Breast Cancer | Phase 3 | Recruiting | UNICANCER | 3380 | 2026-06-26 | 2026-07-31 |
| Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence. ER+ Breast Cancer, Breast Cancer | Recruiting | University Hospital, Grenoble | 81 | 2026-05-26 | 2026-10-02 | |
| Independent, External, Blinded Retrospective Validation of an AI-based Prognostic Assay in ER-Positive/HER2-Negative Early Breast Cancer Locked AI-based prognostic assay - Breast Cancer, Early Breast Cancer | Active not recruiting | Spotlight Medical | 2200 | 2026-04-01 | 2026-04-21 | |
| Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers Tumor biopsy - Early Breast Cancer, Metastatic Breast Cancer | Not applicable | Recruiting | Institut Claudius Regaud | 1050 | 2026-02-06 | 2026-02-10 |
| SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study SHR- A1811 - SHR-A1811, HER2-Postive Breast Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2025-12-20 | 2025-12-29 |
| This Clinical Trial is a Retrospective, Multicenter Cohort Study Evaluating the Real-world Characteristics and Risk of Disease Recurrence in Hormone Receptor-positive, HER2-negative Early Breast Cancer. Early Breast Cancer | Not yet recruiting | Samsung Medical Center | 100000 | 2025-12-17 | 2025-12-30 | |
| MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC Treatment De-Escalation and Early Surgery - TNBC, Triple Negative Breast Cancer, Early Breast Cancer | Phase 2 | Recruiting | Tel-Aviv Sourasky Medical Center | 54 | 2025-11-11 | 2026-01-08 |
| SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response SHR-A1811 - Early Breast Cancer, HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Chuan Wang | 30 | 2025-10-01 | 2025-08-26 |
| A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study) Endoscopic nipple sparing mastectomy, HandX endoscopic instrument - Breast Cancer, BRCA 1 Gene Mutation | Not applicable | Recruiting | Vasileios Kalles | 15 | 2025-09-09 | 2025-12-18 |
| Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients Dalpiciclib, Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) - Early Breast Cancer, Adjuvant Therapy | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 200 | 2025-09-01 | 2025-08-03 |
| Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients Standardized Telenursing, Smart Cancer Care Plus - Early Gastric Cancer, Advanced Gastric Cancer | Not applicable | Recruiting | Ulsan University Hospital | 414 | 2025-07-09 | 2026-02-12 |
| Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer. EG1206A, Perjeta - Early Breast Cancer | Phase 3 | Withdrawn | EirGenix, Inc. | 2025-05-01 | 2025-10-14 | |
| Mediterranean Diet and Inequality in Early Breast Cancer The goal is daily consumption of a minimum of 30 grams of dietary fiber and weekly consumption of a minimum of 30 different plant foods; minimizing the amount of ultra-processed food., Standard Diet - Early Breast Cancer | Phase 2 | Recruiting | Esbjerg Hospital - University Hospital of Southern Denmark | 105 | 2025-03-27 | 2026-09-16 |
| Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer Hypofractionated Radiation Therapy - Early Breast Cancer, Ductal Breast Carcinoma In Situ | Recruiting | National Taiwan University Hospital | 315 | 2025-02-06 | 2025-05-22 |
Showing 20 of 65. Sign in to see all of them.
Breast Neoplasms (65) · Triple Negative Breast Neoplasms (4) · Carcinoma, Intraductal, Noninfiltrating (2) · Motor Activity (2) · Anxiety Disorders (1) · Breast Cancer, Familial (1) · Breast Neoplasms, Male (1) · Colonic Neoplasms (1) · Fatigue (1) · Inflammatory Breast Neoplasms (1) · Joint Diseases (1) · Lung Neoplasms (1) · Medication Adherence (1) · Patient Preference (1) · Skin Diseases (1)
Breast Diseases (65) · Neoplasms (65) · Neoplasms by Site (65) · Skin and Connective Tissue Diseases (65) · Skin Diseases (64) · Behavior (4) · Adenocarcinoma (2) · Breast Carcinoma In Situ (2) · Carcinoma (2) · Carcinoma in Situ (2) · Health Behavior (2) · Neoplasms by Histologic Type (2) · Neoplasms, Ductal, Lobular, and Medullary (2) · Neoplasms, Glandular and Epithelial (2) · Treatment Adherence and Compliance (2)
pertuzumab (6) · Docetaxel (5) · Doxorubicin (5) · Letrozole (5) · Paclitaxel (5) · Trastuzumab (5) · giredestrant (5) · Carboplatin (4) · Cyclophosphamide (4) · Ado-Trastuzumab Emtansine (3) · Anastrozole (3) · Goserelin (3) · Surgical Procedures, Operative (3) · dalpiciclib (3) · exemestane (3)
Hoffmann-La Roche (6) · Pfizer (4) · Fudan University (3) · Novartis Pharmaceuticals (3) · AstraZeneca (2) · Hellenic Cooperative Oncology Group (2) · Henan Cancer Hospital (2) · Institute of Oncology Ljubljana (2) · MedSIR (2) · Aarhus University Hospital (1) · Azienda Ospedaliero-Universitaria Careggi (1) · Centro Hospitalar Universitário de Santo António (1) · Chuan Wang (1) · Consorzio Oncotech (1) · Danish Breast Cancer Cooperative Group (1)
Spain (13) · United States (13) · Italy (12) · China (10) · France (10) · South Korea (10) · Brazil (6) · Canada (6) · Germany (6) · Greece (6) · Hungary (6) · Poland (6) · Russia (6) · Taiwan (6) · Argentina (5)
Zhenzhen Liu (2) · Alessandra Gennari, MD (1) · Antonio Llombart-Cussac, MD (1) · Birgitte V Offersen, phd (1) · Chiung Ing Wong, MRCP, MB ChB (1) · Christine Fredericks (1) · Erika Matos, PhD (1) · Fatima Cardoso, MD (1) · Foteinos-Ioannis Dimitrakopoulos (1)
PMID 25922474, PMID 27336726, PMID 30002437, PMID 30570763, PMID 31461380, PMID 33357420, PMID 35287613, PMID 35594464, PMID 37133584, PMID 37275963, PMID 37318349, PMID 37657462, PMID 38507751, PMID 40504550, PMID 40632989, PMID 40743662, PMID 40996773, PMID 41880605, PMID 42334791
2023 (3), 2017 (1), 2019 (1)